ARTICLE SUMMARY:
The optimism that a resurgent medtech IPO market would continue this year was dashed in the first half of 2016. With the upcoming election likely to bring increased uncertainty resulting in minimal fourth quarter activity, that leaves only a short period for the market to come back. The good news is that M&A remains viable, although continuing consolidation raises concerns.
The last few years marked the long-awaited re-opening of the medtech IPO window after a lengthy period in which the market wasn’t interested in device offerings.
